Drug and Device Injury Legal Resource Blog

Bayer, Janssen Pharmaceuticals and Lead Counsel for Plaintiffs Announce $775 Million Settlement of Xarelto Multidistrict Litigation


On March 25, 2019,  Xarelto manufacturers Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Bayer Healthcare and lead counsel for plaintiffs in the coordinated federal and state court actions announced that they have reached a $775 million private settlement agreement to resolve all lawsuits filed by patients who suffered a bleeding injury after taking Xarelto, a prescription blood thinner drug. According to the agreement, a claims administrator and special master will be appointed to manage the claims process, including any appeals of claim determinations, and will be responsible for determining how funds will be allocated to those who are entitled to payment. 

According to the press release, in addition to addressing lawsuits that are already part of the multidistrict litigation, the settlement agreement resolves newly filed claims that meet certain criteria, including plaintiffs who had retained a lawyer to investigate Xarelto-related personal injury claims before March 11, 2019, register their claim by March 28, 2019, and file a civil action by April 4, 2019. Individuals involved in these lawsuits should contact their personal attorneys to address eligibility questions.

More than 25,000 lawsuits have been filed by Xarelto patients who alleged they suffered injuries such as internal bleeding, stroke and death. The lawsuits claim that the manufacturers downplayed Xarelto's risks and aggressively marketed the drug as an alternative for warfarin in patients needing blood thinners to avoid dangerous clots. The lawsuits allege that doctors and patients were not fully informed of the risks, which allegedly have resulted in life-threatening complications. The coordinated federal Xarelto case is In re: Xarelto (rivaroxaban) Products Liability Litigation, case number 2:14-md-02592 in the U.S. District Court for the Eastern District of Louisiana. 

Read the full press release.


The postings on this blog were created for general informational purposes only and do not constitute legal advice or a solicitation to provide legal services.  Although we attempt to ensure that the postings are complete, accurate, and up to date, we assume no responsibility for their completeness, accuracy, or timeliness.  The information in this blog is not intended to create, and receipt of it does not constitute, a lawyer-client relationship.  Readers should not act upon this information without seeking professional legal counsel.

This blog may contain links to independent third party websites and services, including social media. We provide these links for your convenience, and you access them at your own risk.  We have no control over and do not monitor the content or policies (including privacy policies) of these third-party websites and have no responsibility for, and no liability with respect to, their content, accuracy, or reliability.  Unless expressly stated, we do not endorse any of the linked websites or any product, service, or publication referenced herein or therein.  We will remove a link to any site from this blog upon request of the linked entity.

We grant permission to readers to link to this blog so long as this blog is not misrepresented. This site is not sponsored or associated with any other site unless so identified.

If you wish for Wilentz, Goldman & Spitzer, P.A., to consider representing you, please obtain contact information from the Contact Us area of this blog or go to the firm’s website at www.wilentz.com.  One of our lawyers will be happy to discuss the possibility of representation with you. However, the authors of Wilentz blogs are licensed only in New Jersey and/or New York and do not wish to represent anyone who viewed this site in a state where the site fails to comply with all laws and ethical rules of that state.